YARROW BIOSCIENCE, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
YARROW BIOSCIENCE, INC. (YARW) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$844.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $316.00K.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.16M.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was -$6.41M, a 281.99% decline year-over-year.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$2.49M.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$559.00K.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$8.68M.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was -$2.67M.
- YARROW BIOSCIENCE, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was -$12.97M, a 171.87% decline from fiscal 2019.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $316.00K derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-13 | -$844.00K 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$1.16M S-4/A · filed 2026-06-03 | ||||
| 2025-12-31 | -$12.31M S-4/A · filed 2026-06-03 | ||||
| 2025-06-30 | -$6.41M derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-13 | -$8.90M 10-Q · filed 2026-08-13 | -$6.70M derived: sum of 3 quarters · filed 2026-08-13 | -$5.79M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$2.49M S-4/A · filed 2026-06-03 | -$290.00K derived: sum of 2 quarters · filed 2026-06-03 | $613.00K derived: sum of 3 quarters · filed 2026-06-03 | $4.13M derived: sum of 4 quarters · filed 2026-06-03 | |
| 2024-12-31 | $2.20M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-06-03 | $3.10M derived: sum of 2 quarters · filed 2026-06-03 | $6.62M derived: sum of 3 quarters · filed 2026-06-03 | $6.01M S-4/A · filed 2026-06-03 | |
| 2024-09-30 | $903.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.42M derived: sum of 2 quarters · filed 2025-08-14 | $3.81M 10-Q · filed 2024-11-07 | $4.80M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-06-30 | $3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.91M 10-Q · filed 2025-08-14 | $3.90M derived: sum of 3 quarters · filed 2025-08-14 | $3.98M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$611.00K 10-Q · filed 2025-05-08 | -$612.00K 10-Q · filed 2024-05-09 | $382.00K derived: sum of 2 quarters · filed 2025-05-08 | $459.00K derived: sum of 3 quarters · filed 2025-05-08 | -$658.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $993.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.07M derived: sum of 2 quarters · filed 2025-03-06 | -$47.00K derived: sum of 3 quarters · filed 2025-03-06 | -$559.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.04M derived: sum of 2 quarters · filed 2024-11-07 | -$1.55M 10-Q · filed 2024-11-07 | $969.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.63M 10-Q · filed 2024-08-14 | $892.00K derived: sum of 3 quarters · filed 2024-08-14 | $996.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$512.00K 10-Q · filed 2024-05-09 | $2.01M derived: sum of 2 quarters · filed 2024-05-09 | $2.11M derived: sum of 3 quarters · filed 2024-05-09 | $407.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.63M derived: sum of 2 quarters · filed 2024-03-01 | $919.00K derived: sum of 3 quarters · filed 2024-03-01 | -$8.68M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.60M derived: sum of 2 quarters · filed 2023-11-13 | -$11.20M 10-Q · filed 2023-11-13 | -$14.04M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$11.31M 10-Q · filed 2023-08-14 | -$14.15M derived: sum of 3 quarters · filed 2023-08-14 | -$17.24M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$9.60M 10-Q · filed 2023-05-11 | -$12.44M derived: sum of 2 quarters · filed 2023-05-11 | -$15.53M derived: sum of 3 quarters · filed 2023-05-11 | -$12.48M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$5.93M derived: sum of 2 quarters · filed 2023-03-14 | -$2.88M derived: sum of 3 quarters · filed 2023-03-14 | -$2.67M 10-K · filed 2023-03-14 | |
| 2021-09-30 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$38.00K derived: sum of 2 quarters · filed 2022-11-14 | $167.00K 10-Q · filed 2022-11-14 | -$1.01M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.26M 10-Q · filed 2022-08-12 | $2.08M derived: sum of 3 quarters · filed 2022-08-12 | $1.19M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $205.00K 10-Q · filed 2022-05-12 | -$969.00K derived: sum of 2 quarters · filed 2022-05-12 | -$1.86M derived: sum of 3 quarters · filed 2022-05-12 | -$13.63M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$2.07M derived: sum of 2 quarters · filed 2022-03-17 | -$13.83M derived: sum of 3 quarters · filed 2022-03-17 | -$12.97M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$893.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$12.66M derived: sum of 2 quarters · filed 2021-11-10 | -$11.80M 10-Q · filed 2021-11-10 | $4.74M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$11.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$10.91M 10-Q · filed 2021-08-12 | $5.63M derived: sum of 3 quarters · filed 2021-08-12 | $4.77M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $856.00K 10-Q · filed 2021-05-06 | $17.40M derived: sum of 2 quarters · filed 2021-05-06 | $16.54M derived: sum of 3 quarters · filed 2021-05-06 | $20.86M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $16.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $15.68M derived: sum of 2 quarters · filed 2021-03-04 | $20.00M derived: sum of 3 quarters · filed 2021-03-04 | $18.05M 10-K · filed 2021-03-04 | |
| 2019-09-30 | -$863.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.46M derived: sum of 2 quarters · filed 2020-11-05 | $1.51M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.37M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$1.95M 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | $238.00K 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |